SKSamantha R. Keller

Samantha R. Keller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samantha R. Keller has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patterns of Patient-Reported Awareness About Early-Onset Cancer-Related Infertility Risk

    by Allison D. Morris, Samantha R. Keller, Rachel A. Francis, Ariana von Lersner, Zoe Finer, Heath C. Tolliver, Allison Rosen, Megan Scherer, Alexandra C. Sundermann, Ardaman Shergill, et al.

    PURPOSE: Reproductive care—including discussions about cancer-related infertility risk—is part of the recommended standard of care for all patients with cancer. Despite rising cancer incidence among adults younger than 50 years (early-onset), the evaluation of patients' knowledge about cancer-related infertility risk is limited. We characterized factors associated with lack of awareness of potential cancer-related infertility risk as reported by patients with early-onset cancer. PATIENTS AND METHODS: Using data from the Reproductive Health After Cancer Diagnosis and Treatment (REACT) Study, we identified individuals diagnosed with a first primary early-onset cancer between 2006 and 2021. Awareness of potential cancer-related infertility risk was determined using questionnaires. Logistic regression models were fitted to examine associations between a lack of awareness of cancer-related infertility risk and patient-level factors. RESULTS: Among 636 patients, 28.9% (n = 184) reported never being told that their cancer treatments may affect their fertility. Patients who were aware of a potential cancer-related infertility risk had heard this information, on average, from two unique sources (mean = 2.2, std = 1.3)—with 90.1% of all sources derived from clinical interactions/settings. Patients who self-identified with a racial ethnic minority (REM) population—inclusive of African American/Black, American Indian, Asian, Hispanic/Spanish/Latino/a/x, Middle Eastern or North African, or multiple races—were nearly twice as likely to report an unawareness of infertility risk compared with patients who identified as non-Hispanic White after adjusting for diagnosis age and year, sex, insurance coverage, marital status, and pregnancy history (odds ratio, 1.70 [95% CI, 1.05 to 2.74]; P = .03). CONCLUSION: Three in every 10 patients with early-onset cancer reported never having been told that cancer treatments may affect their fertility. Individual factors contributed to differences in patients' knowledge of potential cancer-related infertility risk. Further study is needed to address this care gap among patients and providers to deliver concordant, high-quality reproductive and oncology care to this growing population.

  • Open Access

    Beyond Paternalism: Rethinking Teratogen and Fertility Counseling Education from a Learner Perspective

    by Lucy Frucht, Nikita Kakkad, Samantha Keller, Gwendolyn P. Quinn

    Medical education plays a crucial role in shaping how future physicians understand and approach the prescribing of teratogenic medications to individuals with the capacity for pregnancy. The teaching that we, as medical students, experienced on this topic relied on blanket cautions derived from current guidelines that either warn students to never prescribe teratogenic medications for "women of childbearing age" or to adhere to rigid contraceptive mandates that lack guidance on contraceptive counseling, reproductive goals, or individual risk. This educational approach erases patient diversity and undermines the principles of reproductive justice. As students who are invested in reproductive health both from an educational and personal standpoint, and with our clinical education taking place in an institution and geographic and political context supportive of comprehensive reproductive health, we felt a better approach was possible. We have witnessed thoughtful, nuanced conversations between patients and providers surrounding the friction between patients' fertility goals and treatment options for other medical conditions. We outline three anecdotes that exemplify the discordance between the limited preclinical instruction most of our classmates receive and the clinical practices we have observed that foreground reproductive justice, inclusivity, and patient-provider trust. Moreover, there is a lack of empiric evidence regarding medical students' knowledge and capacity to conduct teratogenic medication counseling. Existing literature reveals a fragmented and simplified approach taken by many clinicians in prescribing these drugs. These shortcomings are related to those that exist in the context of our personal education, and it is likely that medical education on the topic of teratogenicity, contraception, and fertility is institution dependent. Given that best practices and instructions for approaching these counseling situations are not yet formalized, it is reasonable to assume that students are likely graduating from medical school with varied levels of confidence, skill, and training in this area. We find it necessary that reproductive counseling and contraceptive care for patients on teratogenic medications is taught comprehensively to students to reflect our responsibility as physicians to respect individual reproductive goals, provide inclusive and affirming care, and build trust. The individual tension we have identified within our educational experience sheds light on an area of instruction that may hold significant potential in shaping a generation of thoughtful, effective physicians.